Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile that could differentiate it from other drugs in the class.
The 119-subject, single-arm phase 2 trial showed that glecirasib produced an objective response rate (ORR) of 48% in patients with advanced KRAS G12C-mutated non–small cell lung cancer (NSCLC) when used as a second-line or later therapy, with only 5% of subjects discontinuing therapy due to toxicity.
